{"filings":[{"id":1472077,"accession_number":"0001193805-26-000916","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-07-06T20:22:14+00:00","items":["5.02"],"status":"ready","headline":"Director Tamar Howson resigns; CEO Erik Lundgren appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tamar Howson resigned from Board and Compensation Committee effective June 29, 2026, due to retirement; no disagreement.","On July 5, 2026, Board appointed CEO Erik Lundgren as Class II director until 2028 annual meeting.","Lundgren will not serve on any board committee and receives no additional compensation for director role.","Lundgren's existing employment agreement with Immunic was previously disclosed (May 27, 2026 8-K)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1333120,"accession_number":"0001193805-26-000882","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-06-29T20:05:29+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Immunic shareholders approve 6M share increase to equity plan, elect directors, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2019 Omnibus Equity Plan approved, increasing authorized shares by 6,000,000 to total 8,644,887.","Michael Bonney, Thorvald Nagel, and Richard Rudick elected as Class III directors to serve until 2029.","Baker Tilly US, LLP ratified as independent registered public accounting firm for fiscal year 2026.","Plan amendment vote: 4,391,782 for, 1,361,843 against, 24,538 abstain, and 3,107,100 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":704798,"accession_number":"0001193805-26-000703","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-05-28T11:01:07+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunic presents additional Phase 2 CALLIPER data for vidofludimus calcium in progressive MS at CMSC 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.","Patient-reported outcomes (PHQ-9) showed no worsening of depressive or suicidal thoughts; treatment satisfaction numerically favored drug over placebo at weeks 48 and 120.","Safety data from 467 patients: TEAEs comparable (69.4% vs 68.5%), discontinuation due to TEAEs identical at 2.6% in both arms; no Hy's law cases.","Serious adverse events low and balanced (8.1% vs 6.5%); liver-related TEAEs similar (5.2% vs 5.5%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677278,"accession_number":"0001193805-26-000696","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-05-27T11:00:48+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.","Daniel Vitt resigns as CEO but retains board seat and responsibility for scientific strategy.","Lundgren receives base salary $685K, target bonus 60%, and initial option for 1M shares under inducement plan.","Phase 3 ENSURE trial in relapsing MS expected data readout by year-end 2026; Lundgren to lead toward potential NDA and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":508397,"accession_number":"0001193805-26-000645","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-05-19T11:00:48+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.","Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).","Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.","Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.","Simona Skerjanec remains as board member after transitioning from Interim Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49923,"accession_number":"0001193805-26-000593","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-05-13T11:01:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.","Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.","Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.","Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.","Key European patent granted for vidofludimus calcium with potential exclusivity into 2043."],"consensus_eps_estimate":-0.9308,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91893,"accession_number":"0001193805-26-000516","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunic appoints Michael Panzara as CMO; prior CMO Andreas Muehler resigns, transitions to consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.","Andreas Muehler resigned as CMO effective April 27, 2026; will serve as Senior Medical Officer through April 30, then consultant 10 months at $10K/month.","Panzara granted inducement option for 300K shares (post-split) vesting 50% at 1 year, 50% over 24 months thereafter.","Muehler receives 12 months base salary severance, pro-rated FY2026 bonus, full equity vesting, and 3-year post-termination exercise window.","No disagreement cited for Muehler's departure; Panzara brings >25 years neurology drug development experience including MS approvals at Biogen/Sanofi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91892,"accession_number":"0001193805-26-000495","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Immunic announces 1-for-10 reverse stock split effective April 27, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio; reduces outstanding shares from ~136M to ~13.6M.","Effective 12:01 a.m. ET on April 27, 2026; trading on Nasdaq (IMUX) begins split-adjusted same day.","New CUSIP: 4525EP200; no fractional shares issued, cash in lieu for fractional amounts.","Board determined ratio after stockholder approval on April 14, 2026.","Split intended to meet contractual obligations under Feb 12, 2026 securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91891,"accession_number":"0001193805-26-000461","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Immunic stockholder votes authorize reverse split at 1-for-10, effective April 27, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split with 57.4M votes for, 12.6M against, 0.6M abstentions.","Board set split ratio at 1-for-10, effective 12:01 a.m. ET on April 27, 2026.","New common stock to trade under same symbol 'IMUX' on Nasdaq starting April 27, 2026.","New CUSIP identifier for post-split shares: 4525EP200."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91890,"accession_number":"0001193805-26-000437","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic CEO Daniel Vitt enters $670,000 retention bonus as board searches for new CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Retention bonus of $670,000 payable if Vitt remains employed through 91st day after new CEO hired.","Bonus also payable if Vitt is terminated without cause or resigns for good reason before retention date.","Retention bonus credited against any cash severance due under existing employment agreements.","Agreement includes mutual non-disparagement covenants between Vitt and the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91889,"accession_number":"0001193805-26-000382","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic regains compliance with Nasdaq minimum bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Immunic on Mar 27, 2026 it regained compliance with minimum bid price rule (Rule 5550(a)(2)).","Closing bid price was $1.00 or higher for 20 consecutive business days from Feb 27 to Mar 26, 2026.","Compliance matter is now closed; no further action required to maintain Nasdaq Capital Market listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102296,"accession_number":"0001193805-26-000370","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Immunic appoints Jon Congleton, Mineralys CEO and ex-Teva exec, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Congleton appointed to Board as Class II director effective March 27, 2026; Board size increased from 8 to 9.","Congleton will chair Compensation Committee; received initial grant of options for 500,000 shares vesting over 3 years.","Congleton brings nearly 40 years of biopharma experience; currently CEO of Mineralys Therapeutics.","He previously led the U.S. launch of Copaxone at Teva and held senior roles at Impel NeuroPharma and Nivalis Therapeutics.","Appointment supports Immunic's transition to commercial stage for MS drug vidofludimus calcium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102295,"accession_number":"0001193805-26-000181","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.","Net proceeds ~$187M expected to fund operations into late 2027, including Phase 3 ENSURE trials and NDA submission mid-2027.","CEO Daniel Vitt to transition to senior scientific role; search for new CEO with commercial MS expertise underway.","Simona Skerjanec appointed Interim Chairperson; Thor Nagel (BVF Partners) named to Board.","Net loss for FY2025 was $97.2M ($0.62/share); cash $15.5M at Dec 31, 2025, plus placement proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102294,"accession_number":"0001193805-26-000129","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","3.02","8.01","5.02","9.01"],"status":"ready","headline":"Immunic announces up to $400M private placement and board changes to fund MS trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.","Proceeds to fund completion of Phase 3 ENSURE trials in relapsing MS and initiation of Phase 3 in primary progressive MS.","Simona Skerjanec appointed interim chair; Thor Nagel joins board; Maria Törnsén resigns.","Company entered into royalty purchase agreement with Series B warrant holders for 5% synthetic royalty on vidofludimus calcium sales.","Company plans to search for new CEO with commercial experience; Dr. Vitt to transition to senior scientific role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102293,"accession_number":"0001193805-26-000011","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Immunic transfers to Nasdaq Capital Market after bid price non-compliance; extended grace until June 22, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received approval on Jan 5, 2026 to transfer listing from Nasdaq Global Select to Capital Market, effective Jan 7, 2026.","Failed to regain compliance with $1.00 minimum bid price rule by Dec 24, 2025 deadline.","Transfer grants additional 180-day grace period until June 22, 2026 to meet bid price rule.","Company notified Nasdaq it will seek reverse stock split if needed to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102292,"accession_number":"0001193805-26-000007","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.","Daniel Vitt enters new employment agreement: $305,000 annual salary, 55% target bonus, 50% US working time, $50,000 housing reimbursement.","Vitt's Suspension Agreement with Immunic AG terminated; he will now devote 50% time to Immunic AG with €282,826.50 annual salary and variable remuneration.","Nash's prior Executive Chairman agreement expired Dec 31, 2025; he remains Board Chairman but receives no cash retainer during his Gliomic employment term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118587,"accession_number":"0001193805-25-001570","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.","Cash and equivalents $35.1M as of Sep 30, 2025; company states it lacks adequate liquidity to fund operations for 12 months without additional capital.","R&D expenses $20.0M, down from $21.4M; G&A $6.0M, up from $4.4M.","At ECTRIMS, presented CALLIPER data showing statistically significant 24-week confirmed disability improvement in progressive MS.","Received USPTO Notice of Allowance for patent covering vidofludimus calcium dose strengths for PMS; top-line ENSURE data expected by year-end 2026."],"consensus_eps_estimate":-1.7085,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135057,"accession_number":"0001193805-25-001357","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic presents positive vidofludimus calcium data at ECTRIMS, showing disability improvement in progressive MS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.","Treatment reduced risk of 24-week confirmed disability worsening by 23.8% overall and 33.7% in patients without baseline Gd+ lesions.","Long-term EMPhASIS open-label extension data showed 92.7% of RRMS patients remained free of 24-week confirmed disability worsening at 144 weeks.","Preclinical EAE models demonstrated reduced T cell infiltration and increased neuroprotective markers with vidofludimus calcium.","Data from four poster presentations and one oral presentation highlighted Nurr1 activation as a novel neuroprotective mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135056,"accession_number":"0001193805-25-001164","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.","Cash and equivalents $55.3M; company states insufficient liquidity for 12 months without additional capital.","Phase 2 CALLIPER: vidofludimus calcium reduced 24-week confirmed disability worsening 23.8% overall, 31.3% in PPMS.","Phase 3 ENSURE enrollment completed (1,121 and 1,100 patients); top-line data expected by end of 2026.","Two financings raised $70.1M gross in Q2 2025; R&D expenses $21.4M (+$3.0M YoY)."],"consensus_eps_estimate":-1.683,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135055,"accession_number":"0001193805-25-001008","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunic grants 35M stock appreciation rights to employees and executives at $0.77 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company authorized up to 35M SARs for employees and exec officers; 22,015,000 to exec officers.","Exercise price of $0.77 (July 7 closing); settlement in shares subject to shareholder approval to increase plan shares.","5M SARs exercisable Aug 1, 2026; 30M contingent on warrant exercises and private placement tranches from Jan 2024 offering.","Company intends to seek stockholder approval to amend 2019 Omnibus Equity Incentive Plan to increase authorized shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152027,"accession_number":"0001193805-25-000943","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Immunic receives Nasdaq notice for non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 27, 2025, Nasdaq notified Immunic that its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).","The company has 180 calendar days (until December 24, 2025) to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days.","If not compliant by the deadline, Immunic may apply for an additional 180-day period if it meets other Nasdaq Capital Market listing requirements and intends to effect a reverse stock split.","The notice has no immediate effect on listing; Immunic is evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152026,"accession_number":"0001193805-25-000787","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Immunic shareholders approve 7M share increase in equity plan, elect three Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan amendment increases authorized shares by 7,000,000 to 26,448,871; approved with 32,765,299 for, 10,731,124 against.","Dr. Jörg Neermann, Tamar Howson, and Barclay Phillips elected as Class II directors until 2028.","Baker Tilly US, LLP ratified as independent auditor for fiscal 2025 with 60,427,763 votes for.","Quorum of 61,229,143 shares (63.9% of outstanding) present at June 4, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152025,"accession_number":"0001193805-25-000757","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Immunic prices $65M underwritten offering of pre-funded warrants and Series A/B warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 86.7M pre-funded warrants plus Series A & B warrants at $0.7499 per unit; proceeds ~$65M.","Series A warrants ($0.75 exercise) expire Dec 31, 2025; Series B warrants ($0.75) exercisable from Oct 2025 or upon VWAP ≥$1.25.","Potential additional $130M gross proceeds if Series A and B warrants fully exercised for cash.","Leerink Partners sole bookrunner; B. Riley Securities and Brookline Capital co-managers; close expected June 3, 2025.","Proceeds to fund clinical trials and operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152024,"accession_number":"0001193805-25-000730","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic announces public offering of warrants and posts extended phase 2 CALLIPER data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Commenced underwritten public offering of pre-funded warrants and Series A (expire Dec 31, 2025) and Series B (5-year) warrants.","Leerink Partners sole bookrunner; proceeds to fund clinical trials and general corporate purposes.","Posted updated corporate presentation with extended data from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS.","Offering is subject to market conditions; no assurance of completion or final terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152023,"accession_number":"0001193805-25-000582","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic's vidofludimus calcium reduces disability worsening risk by 30% in PPMS from phase 2 CALLIPER trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.","In PPMS subgroup (n=152), risk reduced by 30%; in non-active SPMS (n=268) by 15%.","Reduced annualized thalamic brain volume loss by 20% vs placebo; T2 lesion burden improved.","Safety profile consistent with prior trials: TEAEs 69.4% (drug) vs 68.5% (placebo); SAEs 8.1% vs 6.5%.","Company plans to discuss phase 3 registration path with healthcare authorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152022,"accession_number":"0001193805-25-000454","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Immunic prices $5.1M registered direct offering of 5.67M shares at $0.90/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Offering led by Aberdeen Investments; Titan Partners as placement agent.","Gross proceeds ~$5.1M; net proceeds ~$4.6M after commissions and expenses.","Shares sold at $0.90 per share under existing shelf registration statement.","Expected to close on April 10, 2025; proceeds to fund clinical trials and operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170857,"accession_number":"0001193805-25-000212","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).","Preclinical 6-month study: IMU-856 reduced body weight gain and food consumption up to -40% vs control in a dose-dependent manner.","Program is Phase 2 ready; company plans to explore IMU-856 as oral treatment for obesity (market >$170B by 2031).","Data also presented at ECCO 2025 digital oral presentation; webcast held Feb 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170856,"accession_number":"0001193805-25-000038","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic posts updated corporate presentation; no new material disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed 8-K on Jan 13, 2025, indicating an updated presentation was posted on its website.","Presentation provided as Exhibit 99.1 but full content not available in filing excerpt.","No specific financial, clinical, or operational updates were identifiable from the filing text.","Investors should access the presentation directly for any material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187819,"accession_number":"0001193805-24-001496","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Daniel Vitt enters new employment agreement for temporary US relocation; board role at Immunic AG paused","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement effective Dec 16, 2024 for CEO's planned <1 year US relocation; board role at Immunic AG suspended.","Base salary $610,000/yr, target annual bonus 55% of salary, eligible for equity awards under existing plan.","Monthly housing reimbursement up to $100,000 during US relocation, plus standard benefits and COBRA continuation.","Severance: 12 months' salary on non-cause/good reason termination (outside change-of-control) if release executed; 18 months if within change-of-control period.","Suspension agreement dated Dec 18, 2024 pauses Immunic AG service agreement until reappointment; no remuneration during suspension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187818,"accession_number":"0001193805-24-001316","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.","Cash $59.1M as of Sep 30, 2024; expected to fund operations into Q3 2025.","Phase 3 ENSURE futility analysis positive: IDMC recommends continuation without sample size increase.","Top-line data from Phase 2 CALLIPER (PMS) expected April 2025; ENSURE-1 completion Q2 2026.","New leadership: Jason Tardio appointed COO/President; Werner Gladdines promoted to CDO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187817,"accession_number":"0001193805-24-001257","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic: IDMC confirms Phase 3 ENSURE trials not futile, recommends continue as planned; CALLIPER data April 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended ENSURE-1 and ENSURE-2 continue unchanged; predetermined futility criteria not met.","Sample size deemed appropriate to address primary endpoint of time to first relapse; no upsizing needed.","Top-line data from Phase 2 CALLIPER trial in progressive MS expected April 2025.","ENSURE program completion on track: ENSURE-1 in Q2 2026, ENSURE-2 in H2 2026.","Immunic remains blinded; drug vidofludimus calcium is a Nurr1 activator for relapsing MS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204331,"accession_number":"0001193805-24-001102","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic hosts MS R&D Day, discusses vidofludimus calcium for relapsing and progressive MS","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Immunic held a multiple sclerosis R&D Day on September 10, 2024.","Presentation focused on vidofludimus calcium (IMU-838) for relapsing and progressive multiple sclerosis.","No specific clinical or financial data from the presentation were disclosed in this 8-K.","The presentation was furnished as Exhibit 99.1 but is not summarized in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204330,"accession_number":"0001193805-24-001079","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immunic extends Executive Chairman Dr. Duane Nash's term to Dec 2025 with salary increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Term of Executive Chairman Duane Nash extended to December 31, 2025 via Addendum No. 6.","Monthly base salary raised to $33,987 from $32,368, inclusive of board retainer.","Addendum effective August 29, 2024; all other employment terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204329,"accession_number":"0001193805-24-001007","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.","Cash $79.7M as of June 30, 2024; expects runway into Q3 2025.","Jason Tardio (ex-Novartis, Biogen) appointed COO and President effective July 12, 2024.","Simona Skerjanec (ex-Roche Neuroscience head) joined Board of Directors July 22, 2024.","Phase 2 CALLIPER top-line data for vidofludimus calcium in PMS expected April 2025; ENSURE Phase 3 RMS trials on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204328,"accession_number":"0001193805-24-000957","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.","Received inducement grant for 100K shares ($1.46) vesting monthly over 3 years; additional 50K shares vesting over 1 year.","Board size increased from 7 to 8 members.","Skerjanec led Roche's Ocrevus commercial launch, generating over $1B in first 10 months.","Company approaching late-stage readouts for vidofludimus calcium in MS; recently hired ex-Novartis/Biogen COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204327,"accession_number":"0001193805-24-000893","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.","Tardio will lead launch preparedness for vidofludimus calcium (IMU-838) and partnership efforts.","Compensation: $500,000 base salary, up to 40% bonus, $120,000 signing bonus, and 500,000 stock options with 4-year vest.","Werner Gladdines promoted from VP to Chief Development Officer, overseeing clinical operations.","Phase 2 CALLIPER trial in progressive MS readout expected April 2025; phase 3 ENSURE trials in relapsing MS due 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221101,"accession_number":"0001193805-24-000791","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunic annual meeting: Vitt, Nash elected Class I directors; auditor ratified; say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Daniel Vitt elected with 43.6M votes for, 6.3M withheld; Dr. Duane Nash elected with 43.4M for, 6.4M withheld.","Ratification of Baker Tilly as independent auditor passed with 59.5M votes for, 281K against, 104K abstain.","Non-binding say-on-pay proposal approved with 47.6M for, 2.2M against, 59.6K abstain.","Meeting held June 11, 2024; quorum of 59.9M shares out of 90.1M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221100,"accession_number":"0001193805-24-000605","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.","Cash $97.3M at March 31, 2024; runway into Q3 2025 after $240M private placement ($80M initial tranche).","Phase 2 CALLIPER (progressive MS) top-line data expected April 2025; Phase 3 ENSURE readout Q2 2026 and H2 2026.","Received fourth US patent for vidofludimus calcium (composition of matter) protecting into 2041.","IMU-856 preparing for phase 2 in celiac disease after positive phase 1b data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240680,"accession_number":"0001193805-24-000341","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Immunic stockholders approve increase in authorized shares from 130M to 500M at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to certificate of incorporation to increase authorized common stock from 130M to 500M shares.","Approved amendment to 2021 ESPP increasing reserved shares by 1M to 1.2M shares.","Approved amendment to 2019 Omnibus Equity Plan increasing authorized shares by 9.1M to 19.4M shares.","Approved repricing of stock options with exercise price above $3.00 to greater of $1.72 or 110% of future closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240679,"accession_number":"0001193805-24-000257","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.","Cash as of Dec 31, 2023: $46.7M; extended to Q3 2025 after $80M Jan 2024 private placement tranche.","Positive interim phase 2 CALLIPER data: vidofludimus calcium reduced NfL in PMS; top-line data expected April 2025.","Phase 3 ENSURE interim futility analysis expected late 2024; first read-out Q2 2026.","New US patents granted for vidofludimus calcium dosing regimens, providing protection into 2041."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240678,"accession_number":"0001193805-24-000022","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.","Second tranche mandatory $80M at $1.716/share conditional on Phase 2b topline data for vidofludimus calcium in PMS (April 2025) and stock price/volume thresholds.","Third tranche up to $80M at same price but cashless settlement possible; total gross proceeds $80M–$240M.","Proceeds to fund vidofludimus calcium, IMU-856, and IMU-381 clinical development; first tranche extends cash runway into Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258172,"accession_number":"0001193805-23-001637","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic extends CEO, CMO, CSO contracts through Dec 2026 with revised compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Daniel Vitt: annual salary EUR 565,653, target bonus up to EUR 311,573, term through Dec 31, 2026.","CMO Andreas Muehler: EUR 231,825 salary (AG) plus $250,000 (Inc.) salary, 50% time to each, term through 2026.","CSO Hella Kohlhof: annual salary EUR 403,375, target bonus up to EUR 161,350, term through Dec 31, 2026.","All three got accelerated stock option vesting on termination and a one-year post-termination exercise period.","New contracts effective Jan 1, 2024, replacing prior agreements; Muehler also signed a separate U.S. employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258171,"accession_number":"0001193805-23-001486","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.","Cash and investments of $59.7M as of Sep 30, 2023; expected runway into Sep 2024.","Phase 2 CALLIPER trial in progressive MS met interim biomarker endpoint: serum NfL improved vs placebo across all subtypes.","Received US patent notice of allowance for vidofludimus calcium in relapsing MS, extending protection to 2041.","CALLIPER enrollment completed (467 pts); top-line data expected April 2025; ENSURE interim futility late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258170,"accession_number":"0001193805-23-001425","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Immunic extends Executive Chairman Duane Nash's term to Dec 2024 with salary increase","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Term extended from Dec 31, 2023 to Dec 31, 2024.","Monthly base salary raised to $32,368 from $30,250 (approx. +7%).","All other terms of the employment agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258169,"accession_number":"0001193805-23-001384","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).","Non-active SPMS subgroup showed 20.1% NfL reduction; PPMS showed 18.8% reduction.","GFAP increased 3.7% for drug vs 4.4% for placebo at 24 weeks; 2.7% vs 6.4% at 48 weeks.","Top-line CALLIPER data expected April 2025; Phase 3 ENSURE interim data late 2024.","NfL reduction numerically higher than historical Ocrevus data in PPMS (22.4% vs 12.4%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275475,"accession_number":"0001193805-23-001054","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.","Cash, cash equivalents and investments at $77.3M as of June 30, 2023.","R&D expenses $21.2M, up from $16.5M YoY, driven by MS and IMU-856 programs.","Interim CALLIPER trial data in progressive MS expected fall 2023; ENSURE top-line late 2024.","Positive Phase 1b IMU-856 data in celiac disease; Phase 2 in active celiac being prepared."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292992,"accession_number":"0001193805-23-000931","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunic shareholders elect Rudick and Törnsén, ratify auditor, approve share plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Richard Rudick and Maria Törnsén elected to three-year terms with ~19.9M votes for each; ~5.65M broker non-votes.","Baker Tilly Virchow Krause, LLP ratified as independent auditor for 2023; 25.5M for, 75K against, 71K abstain.","Amendments to 2019 Omnibus Plan approved: shares authorized increased by 4,440,000 to 10,348,871; evergreen provision removed.","Quorum of 25,616,356 shares represented at meeting out of 44,403,838 entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292991,"accession_number":"0001193805-23-000700","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.","Cash, equivalents and investments $97.1M as of Mar 31, 2023; expected to fund operations into Q4 2024.","Positive phase 1b IMU-856 celiac data: proof-of-concept with improvements in histology, symptoms, biomarkers, nutrient absorption.","Interim results from phase 2 CALLIPER trial of vidofludimus calcium in progressive MS expected H2 2023.","Richard Rudick, M.D. added to board Apr 26, 2023; Vincent Ossipow, Ph.D. to step down June 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292990,"accession_number":"0001193805-23-000659","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunic reports phase 1b IMU-856 data: reduced villous height loss, improved symptoms, no safety issues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.","On first gluten challenge day, placebo symptom increases (nausea 0.8, pain 0.8, diarrhea 0.8) vs. pooled IMU-856 (0.4, 0.5, 0.6) on 5-point scale.","Dose-dependent lessening of serum IL-2 release with IMU-856; citrulline levels increased in active arms while decreasing in placebo.","Vitamin B12 increased by 45.8 pmol/L (80mg) and 74.2 pmol/L (160mg) with IMU-856 vs. 31.0 pmol/L decrease with placebo.","No serious adverse events; two IMU-856 patients showed Q-Marsh histology improvement despite gluten challenge vs. none on placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292989,"accession_number":"0001193805-23-000611","cik":1280776,"company_name":"IMMUNIC, INC.","ticker":"IMUX","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.","Received option to purchase 32,000 shares, vesting monthly over three years, exercise price at grant date closing price.","Dr. Vincent Ossipow will not stand for re-election at 2023 Annual Meeting, continues until then; no disagreement cited.","Board size increased from 7 to 8 directors upon Rudick's appointment.","Rudick brings 35+ years of MS expertise from Cleveland Clinic and Biogen, expected to support vidofludimus calcium development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":208613681.6292857,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-27T23:59:59+00:00|292989"}